Executive Summary

The thulium fiber laser (TFL) is a surgical device emitting at 1.9µm wavelength with super-pulsed capability, designed for both lithotripsy and precise soft tissue surgery. It has emerged as a credible alternative to the holmium:YAG laser, particularly for urinary stone treatment, with additional applications in industrial processing. According to QYResearch‘s Global Thulium Fiber Laser Market Report 2024–2030, the global market is projected to grow from USD 146 million in 2023 to USD 231 million by 2030, expanding at a CAGR of 5.39% during the forecast period. The top three manufacturers—IPG Photonics, Lumibird, and peers—held approximately 56.3% of revenue in 2023. The market’s growth trajectory is shaped by TFL’s procedural efficiency advantages over holmium, its adoption in high-volume urology markets including China, and the technical merits of its 1.94µm wavelength and near-rectangular pulse profile for dusting-based lithotripsy strategies.

Technology Differentiation and Clinical Evidence

The TFL’s fundamental distinction from holmium lies in wavelength and pulse architecture. TFL operates at 1940nm, compared with holmium’s 2100nm, yielding approximately fivefold higher water absorption at body temperature . This property reduces laser penetration depth and alters stone–laser interaction patterns. The pulse profile differs materially: TFL produces near-rectangular pulses of 400–50,000µs duration at lower peak power, while holmium generates asymmetric, shark-fin-shaped pulses of 150–1,500µs at higher peak power . The clinical implication is that TFL favors dusting—producing fine particles for passive clearance—with substantially reduced retropulsion, whereas holmium is better suited to fragmentation with active basket extraction.

The comparative clinical evidence is substantial but not uniformly favorable. A review of 26 comparative studies found TFL reduced operative time by 6–17 minutes and lasering time by up to 50%, with significantly lower retropulsion (p<0.001) and higher stone-free rates in several studies (TFL 91.8–100% vs holmium 67–96%) . Bleeding occurred less often with TFL (5% vs 22%). However, a multicenter randomized trial of 152 patients found no difference in stone-free rate or intraoperative efficiency between pulse-modulated holmium and TFL for renal stone dusting . A Japanese single-center comparison also reported comparable outcomes, with the notable exception of significantly shorter basketing time for TFL (7 vs 21 minutes, p<0.01) . The evidence base thus supports TFL’s efficiency advantages in specific settings—particularly reduced retropulsion and lasering time—while cautioning against assuming universal superiority across all stone scenarios and surgeon techniques.

Competitive Landscape and Concentration Dynamics

The TFL market exhibits moderate concentration, with the top three players holding approximately 56.3% of revenue. IPG Photonics anchors the leading position through its thulium-doped fiber laser platforms, leveraging its industrial fiber laser manufacturing scale and vertical integration. Lumibird (through its Keopsys and Convergent Photonics brands) contributes specialized urology-focused thulium sources, including the CTFL-TERA-HP series offering up to 250W continuous wave and 1.2kW peak power in quasi-continuous mode, with air-cooled options for integration ease . The competitive hierarchy includes medical device OEMs—Quanta System, Olympus, OmniGuide (LISA Laser), Electro Medical Systems, and others—that integrate TFL sources into surgical consoles rather than competing at the component level .

The competitive dynamic is shaped by two distinct market layers. At the component level, IPG Photonics and Lumibird supply laser sources to medical OEMs, competing on beam quality, power stability, and form-factor integration. At the system level, OEMs including Quanta System, Olympus, and Raykeen compete on clinical workflow, fiber delivery ergonomics, and hospital relationships. This structure creates a dual competitive landscape where component suppliers benefit from OEM diversification, while system vendors face direct clinical competition. Recent market data indicates global TFL treatment equipment sales exceeded 500 units in 2024, with the top three manufacturers holding over 40% of that system market .

Regional Dynamics and Adoption Trajectory

China represents the most dynamic adoption market for TFL technology. TFL treatment procedures exceeded 50,000 in 2024, with projections of near-50% annual compound growth from 2025 to 2030 . This trajectory reflects the large installed base of holmium lasers in Chinese hospitals and the clinical community‘s recognition of TFL’s efficiency advantages for dusting-based protocols. Domestic suppliers including Raykeen and Potent are contributing to adoption, though the global system market remains led by European, American, and Japanese manufacturers .

Europe and North America represent mature markets where TFL adoption is progressing through clinical evidence accumulation and hospital capital equipment cycles. The United States market benefits from the presence of academic centers conducting comparative trials and the integration of TFL into existing urology practices as a complement rather than replacement for holmium. Japan began clinical use of TFL for ureteral and renal stones in October 2023, with initial results confirming comparable safety and efficacy to holmium with MOSES technology .

Market Drivers and Technical Challenges

The primary demand driver is TFL’s procedural efficiency advantage in lithotripsy. Reduced retropulsion and shorter lasering time translate directly into operating room time savings—a critical economic consideration for high-volume surgical practices. The technology’s compatibility with dusting strategies aligns with the clinical shift toward office-based and ambulatory stone management, where passive fragment clearance is preferred over active basketing.

Soft tissue surgery applications—including benign prostatic hyperplasia treatment and upper tract urothelial carcinoma ablation—represent a secondary growth vector. TFL’s precise cutting and coagulation capabilities at 2µm wavelength suit endoscopic procedures where hemostasis and minimal collateral damage are priorities.

The technical challenges are material and clinical. TFL systems require specialized fiber delivery with durability under high pulse energies, and the optimal laser settings for different stone compositions and surgical scenarios remain incompletely characterized . The comparative evidence base, while extensive, derives largely from single-center studies with heterogeneous settings and outcome definitions, limiting generalizability . Rare complications—including higher ureteric stricture rates (4.6% vs 1.7%) and isolated sepsis cases in some series—merit vigilance and further investigation .

Industry Outlook

The 5.39% CAGR through 2030 positions TFL as a steady-growth surgical laser category, with demand fundamentals anchored in urology procedure volumes and the gradual displacement of holmium in dusting-oriented practices. The competitive landscape will reward component suppliers capable of delivering stable beam quality and power at competitive cost, and system OEMs capable of demonstrating clinical workflow advantages and building surgeon loyalty. The Chinese market’s rapid adoption trajectory represents both an opportunity—for suppliers with local manufacturing and distribution—and a competitive threat—as domestic system vendors advance in price-sensitive segments. For hospital procurement, the TFL-versus-holmium decision increasingly weighs total procedural economics including operating room time, fiber consumption, and stone-free rates alongside capital cost, with the evidence favoring TFL for dusting protocols and holmium retaining advantages for fragmentation-heavy approaches.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp